Zhou Yan, Zeng Zhi, Dong Xiaoyu, Fei Jianping, Li Baoliang
Changzhou Hospital of Traditional Chinese Medicine, Changzhou, China.
Medicine (Baltimore). 2020 Dec 4;99(49):e23458. doi: 10.1097/MD.0000000000023458.
Reflux esophagitis (RE) is a common disease which is caused by the reflux of stomach and duodenal contents. As a classic prescription of traditional Chinese medicine, Chaihu-Shugan-San (CSS) has been used in the treatment of RE. However, no critically designed overview to evaluate the systematic review of CSS for RE has been carried out. The purpose of this study is to evaluate the efficacy and safety of CSS in the treatment of RE.
We will search the following sources without restrictions for date, language, or publication status: PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) Cochrane Library, EMBASE, MEDLINE, China National Knowledge Infrastructure (CNKI), Wan Fang Database, Chinese Bio-medicine Database, and VIP Chinese Periodical Database. Study selection, data extraction, and assessment of the risk of bias will be performed by 2 reviewers independently. Revman software (v.5.3) will be used to perform the meta-analyses.
This study will provide a comprehensive evaluation of the efficacy and safety of CSS for patients with RE.
The findings will be an available reference to evaluate the efficacy and safety of CSS on RE and provide decision-making reference on which method to choose for clinicians.
10.17605/OSF.IO/5398R.
反流性食管炎(RE)是一种由胃和十二指肠内容物反流引起的常见疾病。柴胡疏肝散(CSS)作为一种经典的中药方剂,已被用于治疗反流性食管炎。然而,尚未对柴胡疏肝散治疗反流性食管炎的系统评价进行严格设计的综述。本研究的目的是评估柴胡疏肝散治疗反流性食管炎的疗效和安全性。
我们将对以下来源进行无日期、语言或出版状态限制的检索:PubMed、Cochrane对照试验中心注册库(CENTRAL)、Cochrane图书馆、EMBASE、MEDLINE、中国知网(CNKI)、万方数据库、中国生物医学数据库和维普中文期刊数据库。研究的选择、数据提取和偏倚风险评估将由两名审阅者独立进行。将使用Revman软件(v.5.3)进行荟萃分析。
本研究将对柴胡疏肝散治疗反流性食管炎患者的疗效和安全性进行全面评估。
本研究结果将为评估柴胡疏肝散治疗反流性食管炎的疗效和安全性提供有效参考,并为临床医生选择治疗方法提供决策参考。
10.17605/OSF.IO/5398R。